These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 7016396)

  • 1. Furosemide kinetics and dynamics after kidney transplant.
    Smith DE; Gambertoglio JG; Vincenti F; Benet LZ
    Clin Pharmacol Ther; 1981 Jul; 30(1):105-13. PubMed ID: 7016396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of probenecid on furosemide kinetics and natriuresis in man.
    Honari J; Blair AD; Cutler RE
    Clin Pharmacol Ther; 1977 Oct; 22(4):395-401. PubMed ID: 902452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Furosemide kinetics and dynamics in patients with cirrhosis.
    Villeneuve JP; Verbeeck RK; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1986 Jul; 40(1):14-20. PubMed ID: 3720175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to furosemide during dehydration with and without naproxen pretreatment of kidney donors and renal transplant recipients.
    Sjöström PA; Odlind BG; Hammarlund-Udenaes M
    Eur J Clin Pharmacol; 1991; 40(3):209-14. PubMed ID: 2060554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of probenecid and spironolactone on furosemide kinetics and dynamics in man.
    Homeida M; Roberts C; Branch RA
    Clin Pharmacol Ther; 1977 Oct; 22(4):402-9. PubMed ID: 902453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous furosemide.
    Li T; Lee MG; Chiou WL
    J Pharmacokinet Biopharm; 1986 Oct; 14(5):495-509. PubMed ID: 3806372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Furosemide disposition in cirrhotic patients.
    Sawhney VK; Gregory PB; Swezey SE; Blaschke TF
    Gastroenterology; 1981 Dec; 81(6):1012-6. PubMed ID: 7286579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary evaluation of furosemide-probenecid interaction in humans.
    Smith DE; Gee WL; Brater DC; Lin ET; Benet LZ
    J Pharm Sci; 1980 May; 69(5):571-5. PubMed ID: 7381747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Furosemide kinetics in renal failure.
    Tilstone WJ; Fine A
    Clin Pharmacol Ther; 1978 Jun; 23(6):644-50. PubMed ID: 648078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of indomethacin on the pharmacokinetics, diuretic response and hemodynamics of furosemide in the dog.
    Data JL; Rane A; Gerkens J; Wilkinson GR; Nies AS; Branch RA
    J Pharmacol Exp Ther; 1978 Aug; 206(2):431-8. PubMed ID: 682123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elimination of furosemide in healthy subjects and in those with renal failure.
    Beermann B; Dalén E; Lindström B
    Clin Pharmacol Ther; 1977 Jul; 22(1):70-8. PubMed ID: 872498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide.
    Keller E; Hoppe-Seyler G; Mumm R; Schollmeyer P
    Eur J Clin Pharmacol; 1981; 20(1):27-33. PubMed ID: 7308269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of furosemide in patients with congestive heart failure.
    Greither A; Goldman S; Edelen JS; Benet LZ; Cohn K
    Pharmacology; 1979; 19(3):121-31. PubMed ID: 523503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased nonrenal clearance and increased diuretic efficiency of furosemide in cystic fibrosis.
    Alván G; Beermann B; Hjelte L; Lind M; Lindholm A; Strandvik B
    Clin Pharmacol Ther; 1988 Oct; 44(4):436-41. PubMed ID: 3168395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of furosemide.
    Lee MG; Li T; Chiou WL
    Biopharm Drug Dispos; 1986; 7(6):537-47. PubMed ID: 3828484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of renal clearance of furosemide by pentopril, an angiotensin-converting enzyme inhibitor.
    Rakhit A; Kochak GM; Tipnis V; Hurley ME
    Clin Pharmacol Ther; 1987 May; 41(5):580-6. PubMed ID: 3032491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydralazine and furosemide kinetics.
    Nomura A; Yasuda H; Katoh K; Akimoto T; Miyazaki K; Arita T
    Clin Pharmacol Ther; 1982 Sep; 32(3):303-6. PubMed ID: 7105621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Furosemide kinetics in patients with hepatic cirrhosis with ascites.
    Fuller R; Hoppel C; Ingalls ST
    Clin Pharmacol Ther; 1981 Oct; 30(4):461-7. PubMed ID: 7285480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between urinary excretion rate, steady-state plasma levels and diuretic response of furosemide in the rat.
    Smith DE; Benet LZ
    Pharmacology; 1979; 19(6):301-6. PubMed ID: 549032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biotransformation of furosemide in kidney transplant patients.
    Smith DE; Benet LZ
    Eur J Clin Pharmacol; 1983; 24(6):787-90. PubMed ID: 6350024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.